Biotech Values

[biomaven0]

It would be close call based on the data we have now.

If they were going for true 3rd-line (T315I or failed both 2nd line drugs) then I am pretty sure the FDA would approve. The only alternative for these patients is a transplant, which has considerable mortality and morbidity. Doctors can take care of the titration themselves - just use the lowest dose that works. That's not something you can really find out from trials within a small population - each patient is different.

Peter